PRMT5-mediated FUBP1 methylation accelerates prostate cancer progression
Journal of Clinical Investigation · 2024
DOI: 10.1172/jci175023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2024. Verfasst von Weiwei Yan und 16 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Multi-Cell Systems, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese A…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, DNA-Binding Proteins, Protein-Arginine N-Methyltransferases, RNA-Binding Proteins. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Strategies beyond hormone-related therapy need to be developed to improve prostate cancer mortality. Here, we show that FUBP1 and its methylation were essential for prostate cancer progression, and a competitive peptide interfering with FUBP1 methylation suppressed the development of prostate cancer. FUBP1 accelerated prostate cancer development in various preclinical models. PRMT5-mediated FUBP1 methylation, regulated by BRD4, was crucial for its oncogenic effect and correlated with earlier biochemical recurrence in our patient cohort. Suppressed prostate cancer progression was observed in various genetic mouse models expressing the FUBP1 mutant deficient in PRMT5-mediated methylation. A competitive peptide, which was delivered through nanocomplexes, disrupted the interaction of FUBP1 with PRMT5, blocked FUBP1 methylation, and inhibited prostate cancer development in various preclinical models. Overall, our findings suggest that targeting FUBP1 methylation provides a potential therapeutic strategy for prostate cancer management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Multi-Cell Systems, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shangha…
- Institute of Functional Nano and Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Collaborative Innovation Center of Suzhou Nano Science and Technology, Soochow Universi…
- Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Nanjing, China.
- National Facility for Protein Science Shanghai, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China.
- State Key Laboratory of Systems Medicine for Cancer, Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yan, W., Liu, X., Qiu, X., Zhang, X., Chen, J., Xiao, K., Wu, P., Peng, C., Hu, X., Wang, Z., Qin, J., Sun, L., Chen, L., Wu, D., Huang, S., Yin, L., & Li, Z. (2024). PRMT5-mediated FUBP1 methylation accelerates prostate cancer progression. Journal of Clinical Investigation. https://doi.org/10.1172/jci175023
Vancouver
Yan W, Liu X, Qiu X, Zhang X, Chen J, Xiao K, et al. PRMT5-mediated FUBP1 methylation accelerates prostate cancer progression. Journal of Clinical Investigation. 2024. doi:10.1172/jci175023
BibTeX
@article{Yan2024,
author = {Yan, Weiwei and Liu, Xun and Qiu, Xuefeng and Zhang, Xuebin and Chen, Jiahui and Xiao, Kai and Wu, Ping and Peng, Chao and Hu, Xiaolin and Wang, Zengming and Qin, Jun and Sun, Liming and Chen, Luonan and Wu, Denglong and Huang, Shengsong and Yin, Lichen and Li, Zhenfei},
title = {PRMT5-mediated FUBP1 methylation accelerates prostate cancer progression},
journal = {Journal of Clinical Investigation},
year = {2024},
doi = {10.1172/jci175023}
}
EUVIMED